Hospital
Saint Francis Hospital Vinita, INC
Saint Francis Hospital Vinita, INC was paid $6.44M by Medicaid between Jan 2018 and Dec 2024, across 55 billing codes. Its largest line is 99283, emergency room visit (moderate) — 31% of everything it billed.
33Billing provider infoSAINT FRANCIS HOSPITAL VINITA, INC
VINITA, OK 74301
VINITA, OK 74301
33aNPI1700334232assigned 09/13/2016
33bProvider typeGeneral Acute Care Hospital
28Total paid$6.44M
24GClaims79,505
24DCodes billed55
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Oklahoma
Rank by total paid#23 of 75
Median peer was paid$3.66M
This provider vs. median1.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 9,049 | $613K | |
| 2019 | 9,729 | $669K | |
| 2020 | 7,855 | $580K | |
| 2021 | 11,693 | $915K | |
| 2022 | 17,228 | $1.38M | |
| 2023 | 15,733 | $1.45M | |
| 2024incomplete | 8,218 | $827K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 31% | 12,407 | 12,192 | $2.01M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 30% | 8,188 | 8,010 | $1.95M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 13% | 2,715 | 2,679 | $866K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 5.2% | 2,749 | 2,674 | $334K |
| 87631 | 4.8% | 2,480 | 2,458 | $310K | |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.9% | 2,927 | 2,758 | $123K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.3% | 901 | 896 | $86K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.1% | 434 | 429 | $74K |
| 80053 | Comprehensive metabolic panel | 1.1% | 6,950 | 6,650 | $71K |
| 71045 | Radiologic examination, chest; single view | 1.0% | 5,236 | 5,140 | $66K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,403 | 1,358 | $59K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,830 | 1,814 | $50K |
43 more codes
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 102 | $49K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 7,160 | $48K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 801 | $47K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 653 | $32K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 437 | $25K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 333 | $24K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 481 | $21K |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,222 | $17K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 997 | $15K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 2,371 | $14K |
| 81001 | <1% | 3,644 | $13K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 162 | $12K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 91 | $12K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 779 | $11K |
| 83690 | <1% | 1,806 | $11K | |
| 84484 | <1% | 971 | $10K | |
| 87070 | <1% | 1,200 | $10K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 1,461 | $9K |
| 87430 | <1% | 494 | $7K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 296 | $7K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 49 | $6K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 293 | $5K |
| 87807 | <1% | 416 | $5K | |
| 83605 | <1% | 442 | $4K | |
| 80061 | Lipid panel | <1% | 305 | $4K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 45 | $3K |
| 84703 | <1% | 417 | $3K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 41 | $2K |
| 87581 | <1% | 47 | $1K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 47 | $1K |
| 87486 | <1% | 47 | $1K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 376 | $914.02 |
| 83880 | <1% | 26 | $873.14 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 43 | $546.43 |
| 82150 | <1% | 73 | $391.68 | |
| 87077 | <1% | 39 | $387.00 | |
| 81025 | <1% | 24 | $176.18 | |
| 94761 | <1% | 978 | $130.27 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 13 | $60.48 |
| 81002 | <1% | 12 | $27.90 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 29 | $10.44 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 13 | $0.96 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 49 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSMITH, BARRY (SYSTEM DIRECTOR, REV CYCLE SUPPORT)
| Provider | Location | Paid |
|---|---|---|
| Saint Francis Hospital Muskogee INC | Muskogee, OK | $16.79M |
| Saint Francis Outreach Services LLC | Tulsa, OK | $15.74M |
| Saint Francis Hospital South LLC | Tulsa, OK | $11.12M |
| Laureate Psychiatric Clinic and Hospital INC | Tulsa, OK | $729K |
| Saint Francis Hospital South LLC | Tulsa, OK | $51K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.